Frédéric Tangy, director of the Vaccine Innovation Laboratory at Institut Pasteur, responds to the announcement of the launch of a massive test program for half a dozen experimental coronavirus vaccines, in which over 100,000 volunteers could participate.
The United States has announced the launch of a very large-scale testing program aimed at accelerating research so that a safe and effective SARS vaccine is available at the end of the year -CoV-2. Frédéric Tangy, director of the Pasteur Institute’s vaccine innovation lab, explains that a program of this size is outstanding. He emphasizes the exceptional nature of this mobilization, the cost of which can amount to several billion dollars.
According to Dr. Francis Collins, director of the National Institutes of Health (NIH), the potential vaccine developed in collaboration with the US biotechnology laboratory Moderna will be the first to be tested during this July program.
The idea is to reduce to a period of just a few months a process that generally takes ten years, which illustrates the urgency of the health crisis that has paralyzed the entire world economic struggle. In total, between 100,000 and 150,000 people can be involved in this initiative, says Dr. Larry Corey, vaccine specialist at the Fred Hutchinson Cancer Center in Seattle, who is participating in the implementation of these trials.